Sana is Incorporating the Tested Immune Evasion Technology to Develop SC451, a HIP-modified, Stem Cell-Derived Therapy as a One-Time Treatment for Patients with Type 1 Diabetes, with a Goal of Normal ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

Sana's first-in-human study shows HIP technology allows islet cells to avoid immune rejection and produce insulin without immunosuppression. Reliance on initial results: The press release heavily ...

UNITY is on track to receive 24-week topline data from its Phase 2b ASPIRE study in diabetic macular edema this quarter, which could provide critical insights for future trials. UBX1325 (foselutoclax) ...

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the poster presentation of a Phase I/II trial of alisertib plus pembrolizumab for the ...

In a new study published in GEN’s sister peer-review journal, GEN Biotechnology, titled, “Exploring Structure-Function Relationships in Engineered Receptor Performance Using Computational Structure ...

ATHENS, Ga. & SAN JOSE, Calif.--(BUSINESS WIRE)--Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored vaccines that harness the ...

New research appearing in the journal Nature Biotechnology answers important questions about the viability of treatments that seek to replace diseased and aged cells in the central nervous system with ...

SAN FRANCISCO, March 23, 2026 (GLOBE NEWSWIRE)-- Siren Biotechnology today announced that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application ...

First-in-Human Study Provides Evidence that Sana’s Hypoimmune (HIP) Technology Enables Transplanted Islet Cells to Avoid Immune Rejection and Produce Insulin Without Immunosuppression Results ...